The leader in computerized cognitive testing
The Signant SmartSignals® Cognitive Drug Research System (CDR System®) revolutionized how we measure changes in cognition in clinical trials. Over 35 years ago, the CDR System was the first computerized solution to challenge paper-and-pencil neuropsychological testing, providing groundbreaking millisecond reaction time, electronic data capture, and parallel forms for repeated administration (addressing the challenge of learning effects). Since then, its widespread adoption has generated the industry’s largest normative database, spanning the broadest range of therapeutic areas, and facilitating meaningful interpretation of test findings.
Our next generation web-based solution uses keyboard input to deliver the same proven administration speed and millisecond accuracy of its predecessor solution, with easier logistics and administration. This was driven by significant research into evolving industry needs and investment into the next generation release of the most widely validated cognitive testing system in clinical trials.
The CDR System assesses aspects of attention, information processing, memory (episodic and working), and executive function. These aspects of cognitive function are essential to regular activities of everyday living.
Administer this highly sensitive battery of computerized cognition tasks, specifically designed for clinical trials, repeatedly throughout your study to identify changes in cognitive function in any participant population.
Each assessment is brief to complete (30 minutes or less depending on the content of the battery) thus reducing participants testing burden.
Signant's medical and scientific experts ensure that for every study, the right battery of tests is selected to meet the study objectives, and to fit with the needs of the patient population. Validated in over 50 languages, and providing multiple parallel forms for each test, the CDR System can address any trial and any testing schedule.
Signant’s CDR System attention battery can be administered in 7-30 minutes by non-specialists. The battery content can be tailored to your protocol’s needs, and data are automatically uploaded to a secure database and immediately available for analysis.
Signant’s attention tests have been used in over 500 cognitive safety assessments over the last 35 years, some of which were used to support product labeling, across a broad range of therapy areas. The cognitive safety attention battery contains the following tests:
Measures alertness and the ability to focus concentration.
Measures sustained and intensive attention.
Measures alertness, the ability to focus concentration, and information processing.
Learn about the CDR System’s role in Alzheimer’s research and how this cognitive assessment tool provides sensitive, reliable data on cognitive...
Cognitive testing for clinical trials. Measure attention, memory, and reaction time to assess drug safety. Web-based, validated in 50+ languages.
Cognitive function and changes are assessed using three general approaches: self-report, informant-report, and performance-based measures. Many scales and questionnaires, such as ECog, are commonly used to measure general cognitive function as well as indication-specific cognition, such as ADAS-COG in dementia studies. Other approaches include sensitive computerized clinical assessment batteries designed to detect subtle cognitive changes that can be applied in any trial for any indication.
While scales and questionnaires vary depending on their purpose, cognitive assessments generally test working memory, episodic memory, attention, tasks, and functions required for everyday life, such as problem-solving and personal care.
Cognitive assessments are used to detect subtle changes in cognitive function, such as impairment or improvements, to determine a treatment’s effect in patients.
Our web-enabled CDR System is a disease-agnostic tool that can provide cognitive testing for any type of population, from healthy volunteers and patients with minor cognitive impairment to patients with dementia.
Featuring bidirectional sensitivity, the CDR System can assess potential deficit and improvement in cognition as exemplified by frequent use in Phase I clinical research studies.